TEVATeva Pharmaceutical Industries Limited

TEVA Stock Price, Valuation & Chart | Teva Pharmaceutical Industries Limited

$37.490+1.30 (+3.59%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic TEVA intrinsic value TEVA calculated fair value vs price

Overview Financials Dividends Ratios

TEVA Historical price chart

TEVA Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization43.66B

PE Ratio12.8

EPS2.93

Trading Volume7.69M

Today's High/Low37.59/35.74

Dividend Yield0.00

52 Week High/Low38.37/18.21

Shares Outstanding1.16B

TEVA Financial Statement

TEVA Analyst ratings

TEVA Analysis & performance metrics

TEVA Company profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and…

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules,…

TEVA Management team

Name

Position

Matthew Shields

Executive Vice President of Global Operations

David R. Mcavoy J.D.

Executive Vice President & Chief Legal Officer

Christopher J. Stevo CFA

Senior Vice President of Investor Relations & Competitive Intelligence

Amir Weiss

Senior Vice President & Chief Accounting Officer

Kathleen Veit

Senior Vice President, Global Compliance & Ethics Officer

Eric A. Hughes M.D., Ph.D.

Executive Vice President of Global R&D and Chief Medical Officer

Richard D. FrancisCEO

President, Chief Executive Officer & Director

Richard Gordon Daniell

Executive Vice President of European Commercial

Name

Position

Matthew Shields

Executive Vice President of Global Operations

David R. Mcavoy J.D.

Executive Vice President & Chief Legal Officer

Christopher J. Stevo CFA

Senior Vice President of Investor Relations & Competitive Intelligence

Amir Weiss

Senior Vice President & Chief Accounting Officer

Kathleen Veit

Senior Vice President, Global Compliance & Ethics Officer

Eric A. Hughes M.D., Ph.D.

Executive Vice President of Global R&D and Chief Medical Officer

Richard D. FrancisCEO

President, Chief Executive Officer & Director

Richard Gordon Daniell

Executive Vice President of European Commercial

Management Team

Matthew Shields

Executive Vice President of Global Operations

David R. Mcavoy J.D.

Executive Vice President & Chief Legal Officer

Christopher J. Stevo CFA

Senior Vice President of Investor Relations & Competitive Intelligence

Amir Weiss

Senior Vice President & Chief Accounting Officer

Kathleen Veit

Senior Vice President, Global Compliance & Ethics Officer

Eric A. Hughes M.D., Ph.D.

Executive Vice President of Global R&D and Chief Medical Officer

Richard D. FrancisCEO

President, Chief Executive Officer & Director

Richard Gordon Daniell

Executive Vice President of European Commercial

Management

Matthew Shields

Executive Vice President of Global Operations

David R. Mcavoy J.D.

Executive Vice President & Chief Legal Officer

Christopher J. Stevo CFA

Senior Vice President of Investor Relations & Competitive Intelligence

Amir Weiss

Senior Vice President & Chief Accounting Officer

Kathleen Veit

Senior Vice President, Global Compliance & Ethics Officer

Eric A. Hughes M.D., Ph.D.

Executive Vice President of Global R&D and Chief Medical Officer

Richard D. FrancisCEO

President, Chief Executive Officer & Director

Richard Gordon Daniell

Executive Vice President of European Commercial

Total 8 executives

TEVA Frequently asked questions

What is Teva Pharmaceutical Industries Limited (TEVA) Stock Price?

Current stock price of Teva Pharmaceutical Industries Limited (TEVA) stock is $37.490. The stock price is +3.59% higher in the session. The intraday range can be seen from this page. Volume of Teva Pharmaceutical Industries Limited (TEVA) stock is 7.69M.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Teva Pharmaceutical Industries Limited (TEVA) stock price going up or down today?

The stock price of Teva Pharmaceutical Industries Limited (TEVA) can change with earnings, company news, and overall market sentiment. Teva Pharmaceutical Industries Limited operates in the Healthcare / Drug Manufacturers - Specialty & Generic market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Teva Pharmaceutical Industries Limited stock expensive at its current price?

Whether Teva Pharmaceutical Industries Limited looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for TEVA on this page is 12.80. EPS on this page is 2.93. Compare those figures with peers and growth expectations before deciding if the current Teva Pharmaceutical Industries Limited price is justified.

How has the stock price of Teva Pharmaceutical Industries Limited (TEVA) performed historically?

Historical performance for Teva Pharmaceutical Industries Limited (TEVA) is shown on the price chart on this page. Review multi-period moves alongside volume to see how TEVA reacted to past earnings and market events.

Should I buy Teva Pharmaceutical Industries Limited (TEVA) stock, at this price?

Buying Teva Pharmaceutical Industries Limited (TEVA) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.